the occurrence of a mixed-clonality pattern in purified CD34+ cell fractions in patients whose granulocytes show homozygosity 4 and the in vitro demonstration of a JAK2 (V617F)-induced proliferative advantage in cell lines. 
the authors reply:
We proposed a two-step model for the role of JAK2 (V617F) in the clonal evolution of myeloproliferative disorders. The first step consists of a G-to-T mutation in one allele of the JAK2 gene that is acquired as a somatic mutation in a hematopoietic progenitor cell or stem cell. This cell gives rise to a clone that is heterozygous for JAK2 (V617F) and expands to replace hematopoietic cells without the JAK2 mutation. The second step consists of a mitotic recombination in one of the progenitor cells or stem cells heterozygous for the JAK2 mutation that generates uniparental disomy and homozygosity for JAK2 (V617F) in one of the two daughter cells. This daughter cell gives rise to a clone that is homozygous for JAK2 (V617F) and expands to replace heterozygous hematopoietic cells. The results of the test described by Tefferi and colleagues provide evidence that confirms the predictions of our model. A strict two-step process applies at the level of individual cells (i.e., each cell can be either heterozygous or homozygous, provided that gene amplification at the JAK2 locus is not involved). In contrast, when cell populations are analyzed, the transition from heterozygosity to homozygosity will be a continuous process, since the proportion of homozygous cells in this mixed population of cells will gradually increase until the homozygous cells fully dominate hematopoiesis. Analyses of mixed-cell populations, such as those of bone marrow or blood, taken during this transition period are expected to show a time-dependent increase of clonal dominance rather than a two-step transition. Thus, the data from Tefferi and colleagues do not contradict our model but instead confirm its predictions. We have applied a quantitative allele-specific polymerase-chain-reaction technique to determine the ratios of wild-type and mutant JAK2 alleles, and we obtained very similar results to those reported here by Tefferi and colleagues.
